Jefferies Upgrades Centessa Pharmaceuticals to Buy, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Kelly Shi upgraded Centessa Pharmaceuticals (NASDAQ:CNTA) from Hold to Buy and increased the price target from $4 to $11, indicating a positive outlook for the company's stock.
November 15, 2023 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Centessa Pharmaceuticals was upgraded by Jefferies from Hold to Buy, with a significant raise in price target from $4 to $11, suggesting a strong confidence in the company's future performance.
Upgrades by analysts, especially with a substantial increase in price target, tend to create positive sentiment among investors and can lead to a short-term increase in stock price. The upgrade from Hold to Buy reflects a bullish stance on the company's prospects, which is likely to be well-received by the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100